<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940260</url>
  </required_header>
  <id_info>
    <org_study_id>082/61</org_study_id>
    <nct_id>NCT04940260</nct_id>
  </id_info>
  <brief_title>Soluble Factors and Renal Outcome in Preeclampsia</brief_title>
  <official_title>Long Term Renal Outcome in Preeclampsia : Role of sFlt-1 / PlGF and Endoglin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangkok Metropolitan Administration Medical College and Vajira Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangkok Metropolitan Administration Medical College and Vajira Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia (PE) is an important complication of pregnancy and can lead to chronic kidney&#xD;
      disease by causing endothelial damage and podocyte loss, Soluble forms-like tyrosine kinase-1&#xD;
      (sFlt-1), placental growth factor (PlGF), sFlt1 / PlGF ratio and endoglin are the biomarkers&#xD;
      for the differential diagnosis of preeclampsia and other diseases. We aim to explore the&#xD;
      correlation of these biomarkers with long term renal function, blood pressure and urine&#xD;
      albumin creatinine ratio (UACR) in PE patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is prospective observational study.Study subjects are pregnant women aged more than 18&#xD;
      years more than 24 weeks of gestation who were diagnosed and classified as preeclampsia or&#xD;
      gestational hypertension by the criteria recommends by the American College of Obstetricians&#xD;
      and Gynecologists (ACOG).14&#xD;
&#xD;
      Severe preeclampsia will be diagnosed by:&#xD;
&#xD;
        -  A systolic/diastolic blood pressure ≥ 140 mmHg occurring on two occasions at least 4&#xD;
           hours apart after 20 weeks of gestation a women whose blood pressure has previously been&#xD;
           normal&#xD;
&#xD;
        -  Proteinuria with excretion of 0.3 gm or more of protein in a 24 hour urine specimen or&#xD;
           urine dipstick results of at least 1+(30 mg per deciliter) on two occasions The&#xD;
           exclusion criteria were chronic hypertension before pregnancy ,chronic kidney disease&#xD;
           according to KDIGO criteria15 ,twin pregnancies,underlying diabetes mellitus .Of the 42&#xD;
           women enrolled in this trial,we excluded 2 patients who had twin pregnancies and history&#xD;
           of diabetes mellitus. Eight women were lost to follow up. The remaining 32 patients&#xD;
           completed the study.&#xD;
&#xD;
      Data collection and Laboratory Measurements Baseline demographic and clinical data will be&#xD;
      recorded as follows: age, gestational age, blood pressure, medication history, parity.&#xD;
      Laboratory data included complete blood count, blood urea nitrogen (BUN), creatinine,&#xD;
      aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, alkaline&#xD;
      phosphate, lactate dehydrogenase (LDH), 24 -hour urine protein excretion and random urine&#xD;
      protein-creatinine ratio. Enzyme-linked immunosorbent assay (ELISAs) for human soluble&#xD;
      endoglin, SFlt1, and free PIGF will be conducted in duplicate with the use of commercial kits&#xD;
      (R§D Systems).&#xD;
&#xD;
      The ratio of SFlt1:PIGF will be calculated. All the participants will be followed up at 3&#xD;
      months and 1 year in which blood pressure, UACR and serum creatinine will be recorded at each&#xD;
      visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between serum sFlt-1/PIGF with long term renal function in preeclampsia</measure>
    <time_frame>1 year</time_frame>
    <description>measure serum sFlt-1/PIGF and eGFR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between serum sFlt-1/PIGF with level of blood pressure in preeclampsia</measure>
    <time_frame>1 year</time_frame>
    <description>measure serum sFlt-1/PIGF and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between serum sFlt-1/PIGF with level of proteinuria in preeclampsia</measure>
    <time_frame>1 year</time_frame>
    <description>measure serum sFlt-1/PIGF and UACR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between serum endoglin with long term renal function in preeclampsia</measure>
    <time_frame>1 year</time_frame>
    <description>measure endoglin and eGFR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between serum endoglin with blood pressure in preeclampsia</measure>
    <time_frame>1 year</time_frame>
    <description>measure endoglin and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between serum endoglin with level of proteinuria in preeclampsia</measure>
    <time_frame>1 year</time_frame>
    <description>measure endoglin and UPCR</description>
  </primary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Renal Function</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Renal function</intervention_name>
    <description>measure eGFR at one year post partum</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>proteinuria</intervention_name>
    <description>measure urine protein creatinine ratio at one year postpartum</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women aged more than 18 years more than 24 weeks of gestation who were diagnosed&#xD;
        and classified as preeclampsia or gestational hypertension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  more than 24 weeks of gestation who were diagnosed and classified as preeclampsia or&#xD;
             gestational hypertension by the criteria recommends by the American College of&#xD;
             Obstetricians and Gynecologists (ACOG)&#xD;
&#xD;
        Severe preeclampsia will be diagnosed by:&#xD;
&#xD;
          -  A systolic/diastolic blood pressure ≥ 140 mmHg occurring on two occasions at least 4&#xD;
             hours apart after 20 weeks of gestation a women whose blood pressure has previously&#xD;
             been normal&#xD;
&#xD;
          -  Proteinuria with excretion of 0.3 gm or more of protein in a 24 hour urine specimen or&#xD;
             urine dipstick results of at least 1+(30 mg per deciliter) on two occasions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        chronic hypertension before pregnancy ,chronic kidney disease according to KDIGO criteria&#xD;
        ,twin pregnancies,underlying diabetes mellitus&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine,Vajira Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007 Nov 10;335(7627):974. Epub 2007 Nov 1. Review.</citation>
    <PMID>17975258</PMID>
  </reference>
  <reference>
    <citation>Magee LA, von Dadelszen P. Pre-eclampsia and increased cardiovascular risk. BMJ. 2007 Nov 10;335(7627):945-6. Epub 2007 Nov 1.</citation>
    <PMID>17975257</PMID>
  </reference>
  <reference>
    <citation>Rudra CB, Williams MA. Monthly variation in preeclampsia prevalence: Washington State, 1987-2001. J Matern Fetal Neonatal Med. 2005 Nov;18(5):319-24.</citation>
    <PMID>16390791</PMID>
  </reference>
  <reference>
    <citation>Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008 Aug 21;359(8):800-9. doi: 10.1056/NEJMoa0706790.</citation>
    <PMID>18716297</PMID>
  </reference>
  <reference>
    <citation>McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis. 2010 Jun;55(6):1026-39. doi: 10.1053/j.ajkd.2009.12.036. Epub 2010 Mar 25. Review.</citation>
    <PMID>20346562</PMID>
  </reference>
  <reference>
    <citation>Khashan AS, Evans M, Kublickas M, McCarthy FP, Kenny LC, Stenvinkel P, Fitzgerald T, Kublickiene K. Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study. PLoS Med. 2019 Jul 30;16(7):e1002875. doi: 10.1371/journal.pmed.1002875. eCollection 2019 Jul. Erratum in: PLoS Med. 2019 Oct 24;16(10):e1002977.</citation>
    <PMID>31361741</PMID>
  </reference>
  <reference>
    <citation>Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5.</citation>
    <PMID>14764923</PMID>
  </reference>
  <reference>
    <citation>Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005 Jan;17(1):3-18.</citation>
    <PMID>15804781</PMID>
  </reference>
  <reference>
    <citation>Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006 Jun;12(6):642-9. Epub 2006 Jun 4. Erratum in: Nat Med. 2006 Jul;12(7):862.</citation>
    <PMID>16751767</PMID>
  </reference>
  <reference>
    <citation>Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003 Jan;188(1):177-82.</citation>
    <PMID>12548214</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangkok Metropolitan Administration Medical College and Vajira Hospital</investigator_affiliation>
    <investigator_full_name>Thananda Trakarnvanich</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

